izpis_h1_title_alt

Cannabinoids and hormone receptor-positive breast cancer treatment
ID Dobovišek, Luka (Avtor), ID Krstanović, Fran (Avtor), ID Borštnar, Simona (Avtor), ID Debeljak, Nataša (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,53 MB)
MD5: 26555D7A0CFCD0CAFC2AED2FCF7A90C8
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/12/3/525 Povezava se odpre v novem oknu

Izvleček
Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70–80% of BCs express estrogen receptors (ER), which predict the response to endocrine therapy (ET), and are therefore hormone receptor-positive (HR+). Endogenous cannabinoids together with cannabinoid receptor 1 and 2 (CB1, CB2) constitute the basis of the endocannabinoid system. Interactions of cannabinoids with hypothalamic–pituitary–gonadal axis hormones are well documented, and two studies found a positive correlation between peak plasma endogenous cannabinoid anandamide with peak plasma 17β-estradiol, luteinizing hormone and folliclestimulating hormone levels at ovulation in healthy premenopausal women. Do cannabinoids have an effect on HR+ BC? In this paper we review known and possible interactions between cannabinoids and specific HR+ BC treatments. In preclinical studies, CB1 and CB2 agonists (i.e., anandamide, THC) have been shown to inhibit the proliferation of ER positive BC cell lines. There is less evidence for antitumor cannabinoid action in HR+ BC in animal models and there are no clinical trials exploring the effects of cannabinoids on HR+ BC treatment outcomes. Two studies have shown that tamoxifen and several other selective estrogen receptor modulators (SERM) can act as inverse agonists on CB1 and CB2, an interaction with possible clinical consequences. In addition, cannabinoid action could interact with other commonly used endocrine and targeted therapies used in the treatment of HR+ BC.

Jezik:Angleški jezik
Ključne besede:hormone receptor, breast cancer, cannabinoids, treatment, CBD, THC, estrogen, cannabinoid receptor
Vrsta gradiva:Članek v reviji (dk_c)
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Leto izida:2020
Status objave pri reviji:Objavljeno
Verzija članka:Založnikova različica članka
Št. strani:12 str.
Številčenje:Vol. 12, iss. 3, art. 525
UDK:616-006
ISSN pri članku:2072-6694
DOI:10.3390/cancers12030525 Povezava se odpre v novem oknu
COBISS.SI-ID:34716889 Povezava se odpre v novem oknu
Datum objave v RUL:06.12.2021
Število ogledov:112
Število prenosov:58
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Gradivo je del revije

Naslov:Cancers
Skrajšan naslov:Cancers
Založnik:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:01.03.2020

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:hormonski receptor, rak dojke, kanabinoidi

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Številka projekta:P1-0390
Naslov:Funkcijska genomika in biotehnologija za zdravje

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Številka projekta:P3-0321
Naslov:Napovedni dejavniki poteka bolezni in odgovora na zdravljenje pri različnih vrstah raka

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj